ClinicalTrials.gg
RecruitingNCT07850076Updated Nov 13, 2026

A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)

A Phase 1/2 interventional study of CTX460 in Alpha-1 Antitrypsin Deficiency (AATD), sponsored by CRISPR Therapeutics. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by CRISPR Therapeutics · Phase 1/2, Interventional, and Treatment

Updated Nov 13, 2026Now RecruitingFirst site in Australia+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia — 7 open to participants now, 8 under way, 2 of them phase 3. alpha 1-Antitrypsin Deficiency · Australia.

Planned enrollment
10th of 18
68 · median 70
Started
2026
with 2 others
Phase 1/2
5 of 18
4 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
CRISPR Therapeutics

Among the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 1/2, and was the 18th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

7 of the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, or all of them as a file.
02

Study summary

A Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).

Read the detailed description

This is a dose finding and expansion study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD). Participants will receive CTX460 via intravenous (IV) infusion.

03

Conditions studied

  • Alpha-1 Antitrypsin Deficiency (AATD)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: ≥18 and ≤75 years.
  2. Able to provide written .
  3. Diagnosis of AATD with PiZZ homozygous genotype.
  4. Serum total AAT level \<11µM in the absence of augmentation.
  5. Emphysema on a CT scan at screening.
  6. A postbronchodilator (FEV1) ≥30% of predicted.
  7. Body weight ≥50 kg.
  8. All male participants must agree to the use of a highly effective method of and their female partners who are women of (WoCBP) are recommended to use a highly effective method of contraception from consent through 6 months after CTX460 infusion.
  9. In Phase 1, female participants must not be WoCBP
  10. In Phase 2, All female participants are eligible if they:

    1. Are not pregnant or breastfeeding and
    2. Agree to the use of a highly effective method of contraception, as defined in the protocol, from consent through 6 months after CTX460 infusion or are , as defined in the protocol.
  11. Participants agree to abstain from alcohol for 2 weeks before and 2 weeks after CTX460 infusion.
  12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. Received augmentation therapy within the 6 weeks prior to CTX460 infusion
  2. Lung or liver transplant or on waiting list for lung or liver transplant
  3. Moderate to severe lung disease other than that may confound results as per investigator discretion
  4. Evidence of significant liver fibrosis/cirrhosis
  5. Participants with cardiovascular disease
  6. Participation in another clinical trial with an drug/product within 30 days of screening or \<5 half-lives of the investigational agent
  7. Exclude participants with an active infection of and
  8. Exclude participants with uncontrolled
  9. Systemic use within 30 days prior to CTX460 administration; inhaled steroids are permitted
  10. Prior treatment with therapy using viral vectors or intended to permanently change a participant's DNA (except for CTX460).
  11. Receipt of LNP vaccines ≤4 weeks prior to screening.
  12. Participants with a history of medically significant or severe reactions to any LNP-based product, including severe reactions or anaphylaxis.
  13. History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the trial or pose an additional risk in administering trial drug to the participant.
  14. Active within past 3 years with the exception of recent basal cell or squamous cell of the skin.
  15. Smokers/vapers (nonsmoking/nonvaping for at least 12 months prior to screening are eligible).
  16. Participants with specified laboratory abnormalities at screening, confirmed by repeat testing when clinically appropriate.
  17. Participants with alcohol use disorder or alcoholic hepatitis within one year prior to screening.
  18. In Phase 1 only, females of or breastfeeding females.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Phase 1

    Phase 1 begins with dose escalation based on a single infusion of CTX460.

    Drug: CTX460

  • Experimental
    Phase 2

    Recommended Phase 2 dose of CTX460.

    Drug: CTX460

Interventions

  • DrugCTX460

    CTX460 is a lipid nanoparticle (LNP) formulation of synthetic nucleotide template polymerase (SyNTase) editor for in vivo gene editing of the serine protease inhibitor A1 (SERPINA1) gene in adults with emphysema associated with severe alpha-1 antitrypsin deficiency (AATD).

06

What researchers measure

Primary outcomes

  1. Phase 1: To evaluate the safety and tolerability of CTX460 in adults with emphysema associated with severe AATD and to determine the recommended Phase 2 dose(s)

    Incidence of DLTs and frequency of AEs

    Time frame: From CTX460 infusion up to 36 months

  2. Phase 2: To assess the efficacy of CTX460 in adults with severe AATD and emphysema

    Absolute blood levels of total AAT at Month 6

    Time frame: 6 months from CTX460 infusion

Secondary outcomes

  1. Phase 1: To assess the preliminary efficacy of CTX460

    Absolute blood levels of total AAT at Month 6

    Time frame: 6 months from CTX460 infusion

  2. Phase 2: To further characterize the safety of CTX460

    Frequency and severity of clinically significant laboratory abnormalities, and clinically significant abnormal vital signs

    Time frame: From CTX460 infusion up to 36 months

  3. Phase 1/2: To assess the efficacy of CTX460

    Rate of change in lung density (g/L per year) as measured by centralized, standardized CT lung densitometry

    Time frame: From CTX460 infusion up to 36 months

  4. Phase 1/2: To assess the efficacy of CTX460

    Time to first moderate or severe COPD exacerbation

    Time frame: From CTX460 infusion up to 36 months

  5. Phase 1/2: To assess the efficacy of CTX460

    Annual rate of moderate or severe COPD exacerbations

    Time frame: From CTX460 infusion up to 36 months

  6. Phase 1/2: To assess the efficacy of CTX460

    Change from baseline in St. George's Respiratory Questionnaire score over time

    Time frame: From CTX460 infusion up to 36 months

  7. Phase 1/2: To assess the efficacy of CTX460

    Change from baseline in FEV1 over time

    Time frame: From CTX460 infusion up to 36 months

  8. Phase 1/2: To assess the effect of CTX460 on blood PD markers

    Blood levels of Z-AAT, M-AAT, and fAAT over time

    Time frame: From CTX460 infusion up to 36 months

  9. Phase 1/2: To characterize the PK of CTX460

    Plasma levels of LNPs over time (ionizable lipid and PEG-lipid)

    Time frame: From CTX460 infusion up to 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Jun 2030, 42 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 30, 2026
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
1 site added — first site in Australia
Show site
  • St. Vincent's Hospital Melbourne · Fitzroy, Australia
Nov 13, 2026
Start date
Oct 31, 2026→Dec 2026
Nov 13, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Australia
    Show site
    • St. Vincent's Hospital Melbourne · Fitzroy, Australia
    Start date Oct 31, 2026→Dec 2026
    + 1 other change: verification date
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850076
Lead sponsor
CRISPR Therapeutics
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Clinical Trials
Contact
medicalaffairs@crisprtx.com
877-214-4634

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion